(Q59649438)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25496884%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

title

MS and related disorders: looking for markers of phenotypes (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25496884%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25496884%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Carla Tortorella

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25496884%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

author name string

Maria Trojano

series ordinal

1

0 references

Carla Tortorella

series ordinal

2

0 references

publication date

1 January 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25496884%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25496884%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25496884%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25496884%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

page(s)

11-13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25496884%20AND%20SRC:MED&resulttype=core&format=json

Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial

24 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970291-1

7 January 2021

Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970291-1

7 January 2021

Defining the clinical course of multiple sclerosis: the 2013 revisions

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970291-1

7 January 2021

Immunoglobulin M oligoclonal bands: biomarker of targetable inflammation in primary progressive multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970291-1

7 January 2021

HLA-DRB1*15 influences the development of brain tissue damage in early PPMS

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970291-1

7 January 2021

XY sex chromosome complement, compared with XX, in the CNS confers greater neurodegeneration during experimental autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970291-1

7 January 2021

Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970291-1

7 January 2021

Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970291-1

7 January 2021

Relationship between NMO-antibody and anti-MOG antibody in optic neuritis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2814%2970291-1

7 January 2021

10.1016/S1474-4422(14)70291-1

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25496884%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

1 reference